Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Summit Technology

This article was originally published in The Gray Sheet

Executive Summary

Firm's LADARVision system premarket approval application supplement seeking expanded labeling for laser in situ keratomileusis (LASIK) vision correction of hyperopia with or without astigmatism up to -6 diopters hyperopia and -6 D astigmatism will be reviewed March 17 by FDA's Ophthalmic Advisory Panel, Summit announces Feb. 10. Request for labeling to include LASIK indication for nearsightedness (up to -11 diopters, up to 6 D astigmatism) is still pending at FDA. Designed and developed by Summit's Autonomous Technologies unit, the device currently is approved for photorefractive keratectomy treatment of myopia up to -10 D and up to -4 D astigmatism
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT012960

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel